Jean Perrin Center
The RFID trial focuses on breast localization in patients with non-palpable breast cancers. It aims to demonstrate the improvement in patient comfort when using the Radio Frequency Identification (RFID) tag and LOCalizer™ device compared to the gold standard device.
Breast Neoplasm Female
RFID tags
Wire localization
It is an observational, prospective, single-center, 2-arm (RFID group vs. standard gold), non-randomized and category 3 comparative study. The RFID trial focuses on breast localization in patients with non-palpable breast cancers. These patients will benefit from a mastology consultation: consent will then be acquired. The RFID tag or the gold standard localization will be put in place during this consultation (one day before surgery). Patients will fill in their questionnaire in two steps: * during the installation of the device (RFID tag or wire localization) to evaluate the patient's pain, * then at the 1-month post-operative consultation to assess pain in the interval until surgery Radiologists and surgeons will fill out the questionnaire dedicated to them after each procedure.
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 80 participants |
Official Title : | RFID Trial: Localization of Non-palpable Breast Lesions Using Radiofrequency Identification Tags or Wire |
Actual Study Start Date : | 2021-05-15 |
Estimated Primary Completion Date : | 2023-04-24 |
Estimated Study Completion Date : | 2023-04-24 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | FEMALE |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Jean PERRIN Center
Clermont-Ferrand, France, 63011